The E3 Ubiquitin Ligase RNF7 Negatively Regulates CARD14/CARMA2\textsubscript{sh} Signaling

Gianluca Telesio \textsuperscript{1}, Ivan Scudiero \textsuperscript{1}, Maddalena Pizzulo \textsuperscript{1}, Pellegrino Mazzone \textsuperscript{1}, Tiziana Zotti \textsuperscript{2}, Serena Voccola \textsuperscript{3}, Immacolata Polvere \textsuperscript{3}, Pasquale Vito \textsuperscript{1,2,3,*} and Romania Stilo \textsuperscript{3}

\textsuperscript{1} Biogem Consortium, Via Camporeale, 83031 Ariano Irpino (AV), Italy; luca.telesio@libero.it (G.T.); scudieroi@gmail.com (I.S.); maddalena.pizzulo@biogem.it (M.P.); pellegrinomazzone@gmail.com (P.M.)
\textsuperscript{2} Genus Biotech, Università degli Studi del Sannio, Strada Statale Appia, 82010 Apollosa (BN), Italy; tintz.zotti@gmail.com
\textsuperscript{3} Dipartimento di Scienze e Tecnologie, Università degli Studi del Sannio, Via Port’Arca 11, 82100 Benevento, Italy; serena.voccola@virgilio.it (S.V.); stardust88@live.it (I.P.); romstilo@unisannio.it (R.S.)
* Correspondence: vito@unisannio.it; Tel.: +39-08-2430-5152

Received: 25 September 2017; Accepted: 27 November 2017; Published: 1 December 2017

Abstract: The three CARD-containing MAGUK (CARMA) proteins function as scaffolding molecules that regulate activation of the pro-inflammatory transcription factor NF-\kappa B. Recently, mutations in CARMA2 have been linked to psoriasis susceptibility due to their acquired altered capacity to activate NF-\kappa B. By means of two-hybrid screening with yeast, we identified RING finger protein 7 (RNF7) as an interactor of CARMA2. We present evidence that RNF7 functions as a negative regulator of the NF-\kappa B-activating capacity of CARMA2. Mechanistically, RNF7 influences CARMA2 signaling by regulating the ubiquitination state of MALT1 and the NF-\kappa B-regulatory molecule NEMO. Interestingly, CARMA2\textsubscript{short} (CARMA2\textsubscript{sh}) mutants associated with psoriasis susceptibility escape the negative control exerted by RNF7. In conclusion, our findings identify a new mechanism through which the ability of CARMA2 to activate NF-\kappa B is regulated, which could have significant implications for our understanding of why mutations of this protein trigger human psoriasis.

Keywords: CARD14; CARMA2\textsubscript{sh}; RNF7; NF-\kappa B; psoriasis; MALT1; ubiquitin; B-cell lymphoma/leukemia 10 (BCL10)

1. Introduction

The CARD-containing MAGUK (CARMA) family of proteins consists of the three evolutionarily conserved proteins CARD11/CARMA1 (CARMA1), CARD14/CARMA2 (CARMA2) and CARD10/CARMA3 (CARMA3) [1,2]. CARMA proteins share a similar structure, consisting of an N-terminal CARD domain followed by a coiled-coil (CC) domain, a linker region, and a C-terminal membrane-associated guanylate kinase domain (MAGUK), which in turns comprises PSD-95/Dlg1/ZO-1 (PDZ), SRC Homology 3 Domain (SH3), and guanylate kinases (GUK) subdomains [1,2]. Functionally, CARMA proteins behave as scaffolding molecules that can activate the pro-inflammatory transcription factor NF-\kappa B [1,2]. More specifically, the CARD domains of CARMA proteins interact with the CARD domain of B-cell lymphoma/leukemia 10 (BCL10), which binds the protease Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1). The resulting CARMA–BCL10–MALT1 (CBM) complex then mediates downstream signaling, including the recruitment and activation of the IKK complex and activation of the NK-\kappa B pathway [1–3]. While CARMA1 and CARMA3 play an essential role in NF-\kappa B signaling induced by antigen receptors and certain G-protein-coupled receptors (GPCRs), respectively [1,2], in human keratinocytes CARMA2 plays an indispensable role in the signal transduction pathway that links pathogen-associated molecular pattern recognition to NF-\kappa B activation [4]. Recent works have
shown that mutations in CARMA2 segregate with several human inflammatory skin disorders, including familial and non-familial cases of psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, palmoplantar pustular psoriasis, and pityriasis rubra pilaris [5–18]. Many of the CARMA2 mutations associated with human skin disorders result in an increased activity of NF-κB transcription factor [2,4,5,19].

Similar to CARMA1 and CARMA3, activation of NF-κB promoted by CARMA2 is also mediated by the CBM complex [20–22]. Thus, to identify novel regulators of CARMA2 signaling, we carried out two-hybrid screening using CARMA2 short (CARMA2sh) [22] as a bait. We identified RING finger-containing protein 7 (RNF7) as a novel CARMA2 interactor. We show evidence that RNF7 negatively regulates CARMA2-mediated NF-κB signaling, whereas a psoriasis-linked CARMA2 mutant escapes this negative regulation.

2. Results

In order to identify novel interactors of CARMA protein, a set of two-hybrid screenings were carried out in the yeast reporter strain AH109. When CARMA2sh, the CARMA2 isoform predominantly expressed in human keratinocytes [5,23] was used as a bait, several clones were isolated in multiple independent copies encoding for the RING finger protein 7 (RNF7), a 113-amino acid protein also referred to as the sensitive to apoptosis gene (SAG) [24,25], regulator of cullins 2 (ROC2) or RING-box 2 (Rbx2). RNF7 was originally identified as a redox-inducible anti-oxidant protein [24] and is also a component of E3 ubiquitin ligases with E3 ubiquitin ligase activity [26]. Subsequent experiments carried on with one of these library plasmids confirmed the interaction of RNF7 with CARMA2sh in the reporter yeast strain (Table 1).

Table 1. Interaction of CARMA2short (CARMA2sh) with RING finger protein 7 (RNF7) in the yeast two-hybrid assay.

| Protein Fused to GAL4 Domain | Yeast Growth on Selective Media |
|-----------------------------|--------------------------------|
| DNA-Binding | Activating | - | RNF7 | - | RNF7 | - | CARMA2sh | RNF7 | + | CARMA2sh |

Yeast AH109 was transformed with CARMA2sh fused to the GAL4-DNA binding domain together with the indicated cDNAs fused to the GAL4-activating domain. The cDNA encoding for FADD served as a putative negative control. Interactions were examined by yeast growth on selective media; assays were done for 10 independent transformants. Yeast colonies were scored as positive (+) when growth developed within 24–36 h; a negative (−) was scored when growth failed to develop within 1 week.

To test for a direct association between CARMA2sh and RNF7 in mammalian cells, HEK293T cells were cotransfected with plasmids expressing FLAG-tagged CARMA2sh together with a vector encoding for HA-tagged RNF7 (Figure 1A). Cell lysates were immunoprecipitated with anti-FLAG-coated beads, and the presence of coprecipitating RNF7 was monitored by immunoblot experiments with anti-HA antibody. The result shown in Figure 1A indicates that CARMA2sh coprecipitates with RNF7 in transfected cells. Next, we tested whether CARMA2sh and RNF7 endogenously interact in the HaCaT keratinocytic human cell line, which expresses both proteins. Indeed, as shown in Figure 1B, when protein lysates extracted from HaCaT cells where immunoprecipitated with an anti-CARMA2 antibody but not the control antibody anti c-myc, coprecipitating RNF7 was detected by an immunoblot assay. Interaction of RNF7 with CARMA2sh slightly increased following stimulation of HaCaT cells with Interleukin 1 beta (IL-1β).
Figure 1. RNF7 binds to CARMA2sh. (A) HEK293T cells were cotransfected with a plasmid encoding for HA-tagged RNF7 together with a FLAG-tagged expression vector empty or encoding for CARMA2sh. Twenty-four hours later, lysates were immunoprecipitated with anti-FLAG antibodies and analyzed for coprecipitating HA-RNF7 by Western blot assay. (B) HaCaT cells were left untreated or stimulated with IL-1β for 30 min. Cell lysates were then prepared, immunoprecipitated with anti-RNF7 or anti-myc control antibodies, and analyzed for coprecipitating CARMAsh by Western blot assay. IP: Immunoprecipitation; WB: Western Blot.

Since CARMA2sh is implicated in the NF-κB signaling pathways, we then investigated for an involvement of RNF7 in this pathway using a luciferase-based reporter assay. Indeed, as shown in Figure 2A, RNF7 significantly represses, in a dose-dependent manner, NF-κB activation elicited by CARMA2sh expression. Interestingly, the NF-κB activation produced by the psoriasis-linked mutants CARMA2shE138A and CARMA2shE142G were not affected by RNF7 expression (Figure 2B), despite both mutants still being associated with RNF7 (Figure 2C).

Figure 2. Cont.
Figure 2. RNF7 represses the NF-κB-inducing activity of CARMA2sh. (A) HEK293T cells were transiently cotransfected with expression vectors encoding for CARMA2sh (1 µg) and RNF7 in the indicated amount, together with NF-κB-luciferase and β-galactosidase reporter vectors. Twenty-four hours after transfection, cell lysates were prepared and luciferase activity was measured. Data shown represent relative luciferase activity normalized against β-galactosidase activity and are representative of at least ten independent experiments done in triplicate. Lower panel: A fraction of the cell lysate was analyzed by immunoblot assay to monitor protein expression. (B) HEK293T cells were transiently cotransfected as in (A) with expression vectors encoding for wild type (wt) or psoriasis-linked mutants of CARMA2sh (1 µg), with or without a vector encoding for RNF7. The total amount of transfected DNA was kept constant by adding empty vector. Twenty-four hours after transfection, cell lysates were prepared and luciferase activity was measured. Data shown represent relative luciferase activity normalized against β-galactosidase activity and are representative of at least 10 independent experiments done in triplicate. Lower panel: A fraction of the cell lysate was analyzed by immunoblot assay to monitor protein expression. (C) Upper panel: HEK293T cells were cotransfected with a plasmid encoding for HA-tagged RNF7 together with a FLAG-tagged expression vector empty or encoding for wt CARMA2sh or psoriasis-associated mutant forms of CARMA2sh. Twenty-four hours later, lysates were immunoprecipitated with anti-FLAG antibodies and analyzed for coprecipitating HA-RNF7 by Western blot assay. Lower panel: Densitometric analysis of RNF7 associated to wt and mutant forms of CARMA2sh. IP: Immunoprecipitation; WB: Western Blot.

We have previously shown that in human keratinocytes CARMA2sh plays a key role in the signal transduction pathway that connects pathogen-associated molecular pattern (PAMP) recognition to NF-κB activation [4]. In fact, exposure to PAMPs activates NF-κB following agonistic binding to pattern recognition receptors, which includes members of the toll-like receptor family expressed on human keratinocytes [27]. Interestingly, we noted that RNF7 expression is induced in HaCaT cells exposed to heat-killed bacterial (E. coli and S. aureus) or fungi (C. valida) cells or the inflammatory cytokine IL-1β (Figure 3A).
Figure 3. RNF7 expression represses NF-κB signaling upon pathogen-associated molecular pattern (PAMP) recognition. (A) HaCaT cells were left in phosphate-buffered saline (PBS) or exposed to the indicated heat-killed microorganisms or IL-1β (10 ng/mL) for 6 h, and the expression level of RNF7 was monitored by real-time PCR. Graph show the fold changes respect to the cells left in PBS. Data shown is representative of three independent experiments done in triplicate. (B) HaCaT cells were infected with a lentiviral vector expressing RNF7 or control GFP. Forty-eight hours later, cells were left in PBS or exposed to the indicated heat-killed microorganisms for 6 h, and the expression levels of selected NF-κB target genes were monitored by real-time PCR. Data shown represents the fold changes respect to the GFP-transfected cells left in PBS. Data were analyzed by Student’s t-test, and a p-value ≤ 0.05, indicated with an * was considered significant. Data shown is representative of at least three independent experiments done in triplicate.

Thus, we tested whether expression of RNF7 influences NF-κB activation following PAMP exposure. For this, HaCaT cells were infected with a retroviral vector encoding for RNF7 or control GFP, and the induction of several NF-κB target genes following exposure to heat-killed microorganisms or IL-1β was monitored by real-time PCR. Indeed, as shown in Figure 3B, expression of RNF7 significantly reduces the induction of all the NF-κB target genes assessed.

We next tried to abrogate RNF7 expression in HaCaT cells and primary human normal epidermal keratinocytes (NEK) using short hairpin RNAs targeting human RNF7. By abolishing RNF7 expression, in fact, we would expect a greater NF-κB response following PAMP stimulation. However, depletion of RNF7 expression in both HaCaT and NHEK resulted in a marked reduction of cellular viability (Figure 4), indicating that RNF7 expression is required for survival in cultured cells.
Figure 4. RNF7 depletion results in cell death (A) Left panel: HaCaT cells were infected with retroviral vectors encoding for two different short hairpin RNAs (shRNAs) targeting RNF7 or a control shRNA (scramble). After selection, RNF7 mRNA levels normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were quantified by real-time PCR. Right panel: In the same cells RNF7 expression was monitored by immunoblot assay. (B) HaCaT cells and (C) human normal epidermal keratinocytes were infected with a lentiviral vector expressing a scramble sequence or shRNAs targeting RNF7 and cell viability was monitored at the indicated time points by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (D) 20× phase contrast micrographs of the human normal epidermal keratinocytes used in the experiment shown in (C). NEK: normal epidermal keratinocytes.

Since RNF7 is a ubiquitin ligase, and ubiquitination events play an important role in the CBM-mediated activation of the NF-κB pathway [1], we investigated whether RNF7 could modify such ubiquitination reactions. In fact, as shown in Figure 5A, transfection of CARMA2sh in HEK293T cells results in ubiquitination of BCL10, and the simultaneous expression of RNF7 does not interfere with that ubiquitination event. Similarly, RNF7 does not alter the ubiquitination state of CARMA2sh (Figure 5B), which has been reported as one of the mechanisms through which the function of CARMA protein is regulated [28]. However, RNF7 significantly reduces the ubiquitination of MALT1 and NF-kappa-B essential modulator (NEMO) induced by CARMA2sh expression (Figure 5B,C). Interestingly, RNF7 abrogates ubiquitination of MALT1 and NEMO induced by the psoriasis-associated mutant CARMA2shE138A, but not that induced by the psoriasis-associated mutant CARMA2shE142G.
3. Discussion

Long known as the least characterized of the three CARMA proteins, the recently discovered involvement of CARMA2 in inflammatory diseases of human skin has spurred intense research on this protein. Thus, recent data has shown that similarly to CARMA1 and CARMA3, the NF-κB signaling triggered by CARMA2 requires the BCL10 and MALT1 proteins organized in the CBM complex [4,20–22]. Also, similarly to CARMA1 and CARMA3, NF-κB signaling induced by CARMA2 is abrogated by the de-ubiquitinase A20 [20], implying that ubiquitination events are also involved in the regulation of CARMA2 function. In this work we have identified RNF7 as a CARMA2-associated molecule capable of negatively regulating its ability to activate NF-κB transcription factor. This data is of particular significance since most of CARMA2 mutants associated with psoriasis are characterized by promoting a deregulated, increased activation of NF-κB [2,19]. It is therefore interesting to note that...
RNF7 is able to repress the NF-κB-inducing activity of wild type (wt) CARMA2\textit{sh}, but not that of the two psoriasis-associated mutants CARMA2\textit{sh}E138A and CARMA2\textit{sh}E142G.

Our data is consistent with a recent paper by Pedersen et al., showing that RNF181, a protein belonging to the same family as RNF7, negatively regulates induction of NF-κB mediated by CARMA1 in lymphoid cells [29]. However, the mechanisms through which RNF181 and RNF7 modulate CARMA proteins signaling seem to be different. In fact, RNF181 controls CBM-mediated NF-κB signaling by regulating the expression level of BCL10 protein. However, in our experiments, the expression levels of BCL10, CARMA2\textit{sh}, MALT1, and key NF-κB regulators such as TRAF2, TRAF6, and NEMO are not affected by RNF7 expression (Figure 6 and data not shown).

In our experiments, RNF7 expression promotes deubiquitination of MALT1 and NEMO, which is a well-known post-translational modification that affects activation of NF-κB mediated by the CBM complex [30–33]. Thus, it appears that there are multiple mechanisms employed by RNF proteins to regulate CARMA proteins function. RNF7 possess a E3 ubiquitin ligase activity [26], and seems to be unlikely that just a RING finger protein, like RNF7, can mediate a deubiquitination reaction. This evidence clearly indicates that the deubiquitination of MALT1 and NEMO promoted by RNF7 occurs through an indirect mechanism, raising the fascinating possibility that RNF7 may target for degradation an upstream molecule(s) responsible for ubiquitination of MALT1 and NEMO. That intriguing scenario, though, remains to be demonstrated.

Finally, a particular comment should be made on the behavior of the CARMA2\textit{sh} mutants associated with psoriasis analyzed in this study. In fact, while with regard to NF-κB activation both mutants CARMA2\textit{sh}E138A and CARMA2\textit{sh}E142G are insensitive to the negative control exercised by RNF7 (Figure 2B), they behave differently with regard to MALT1 ubiquitination. In fact, RNF7

\textbf{Figure 6.} The CARMA–BCL10–MALT1 (CBM) complex expression level was not affected by RNF7. HEK293T cells were left untransfected or transfected as indicated. Twenty-four hours later, lysates were prepared and the expression level of the indicated proteins was monitored by immunoblot assay. CARMA: CARD-containing MAGUK.
abrogates ubiquitination of MALT1 induced by CARMA2shE138A expression, but not MALT1 ubiquitination induced by CARMA2shE142G expression (Figure 4B), indicating that the various CARMA2 mutants associated with psoriasis so far identified can cause the disease through different molecular mechanisms. Much work is still needed to decipher these mechanisms.

4. Materials and Methods

4.1. The Two-Hybrid Screening

The two-hybrid screening carried out using CARMA2sh as a bait as described in [34]. Briefly, yeast strain AH109 GAL4−/− was first transformed with pGBK7 plasmids carrying a CARMA2sh cDNA bait fused with DBD of GAL4 using the lithium acetate/PEG 3000 procedure. Transformant colonies were selected on synthetic dropout plates lacking tryptophan. Expression of bait fusion proteins was assessed by immunoblot analysis. For library screening, yeast AH109 expressing GAL4DBD–CARMA2sh was transformed with a human fetal brain cDNA library cloned in pACT2 vector (Clontech) in fusion with GAL4TAD. Then, 2 × 10^6 clones were screened for interaction with GAL4DBD–CARMA2sh using selective growth on minimal medium lacking nutrients for which biosynthesis is mediated by genes under the control of GAL4 transcriptional activity.

4.2. Cell Culture and Tranfection

HEK293T and HaCaT cells were obtained from the ATCC and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% FCS. Normal human epidermal keratinocytes (NHEKs) were purchased from Lonza and cultured according to the provided instructions. HEK293T cells were transfected by calcium phosphate precipitation; NHEKs were transfected using DreamFect Gold Transfection Reagent (OZ Biosciences Inc., Marseille, France) according to the manufacturer’s instruction. HaCaT were transfected with Lipofectamine® 3000. Retroviral infections were carried out as previously described [35,36].

4.3. Immunoblot Analysis and Coprecipitation

Cell lysates were made in lysis buffer (150 mM NaCl, 20 mM HEPES, pH 7.4, 1% Triton X-100, 10% glycerol) and a mixture of proteases inhibitors (Protease Inhibitor Cocktail, Roche) according to the manufacturer’s instructions. Proteins were separated by SDS–PAGE, transferred onto nitrocellulose membrane, and incubated with primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences Corp., Piscataway, NJ, USA). Blots were developed using the enhanced chemiluminescence (ECL) system (Amersham Biosciences Corp.). For co-immunoprecipitation experiments, cells were lysed in lysis buffer and immunocomplexes were bound to protein A/G (Amersham Biosciences) for 2 h at 4 °C. Immunocomplexes were extensively washed, resolved by SDS–PAGE, and analyzed by immunoblot assay. Antisera and monoclonal antibodies were the following: anti-FLAG, anti-β-Actin, (Sigma-Aldrich, St. Louis, MI, USA); anti-HA, anti-myc, anti-MALT1, anti-CARMA2, anti-NEMO, anti-ubiquitin, (Santa Cruz Biotechnology, Dallas, TX, USA); and anti-RNF7 (Abcam, Cambridge, UK). The anti-BCL10 antibody was described in [37].

4.4. Luciferase and β-Galactosidase Assays

To assess for NF-κB activation, cells were co-transfected in 6-well plates with 0.2 µg of pNF-κB-luc (Clontech Laboratories, Mountain View, CA, USA) and 0.1 µg of pRSV-βGal (Addgene, Cambridge, MA, USA) plus each expression plasmid. When necessary, the total amount of transfected plasmidic DNA (2 µg) was kept constant by adding empty vector. pNF-κB-luc encodes the firefly luciferase reporter gene under the control of a minimal (m) CMV promoter and tandem repeats of the NF-κB transcriptional response element. The plasmid RSV-βGal, expressing β-galactosidase, was added to the transfection mixture in order to normalize for the efficiency of transfection. After transfection and
treatments, luciferase activity was determined with Luciferase Assay System (Promega, Madison, WI, USA). For measurement of β-galactosidase activity, 20 µL of cell lysates diluted 100-fold with 0.1 M potassium phosphate buffer were mixed with 200 µL of Galactone (Tropix, Bedford, MA, USA) that were diluted 100-fold with 0.1 M potassium phosphate and 1 mM magnesium chloride, pH 7.8, for 1 h at room temperature. Then, β-galactosidase activity was measured after addition of 300 µL of Emerald (Tropix). Luciferase activity was normalized on β-galactosidase activity and expressed in arbitrary units.

4.5. Real-Time RT-PCR

Total RNA was isolated from cells or tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The reverse transcriptase reaction was performed using 1 µg of total RNA in a 20 µL reaction and 1 µL of the resulting cDNA was used in the subsequent amplification step along with 300 nM of each primer. The geometric mean values of β-actin and succinyl-CoA synthetase β-subunit fragment were used as normalization factors. The relative transcription level was calculated by using the ∆∆Ct method. Real-time PCR reactions were performed in triplicate by using the SYBR Green PCR Master Mix (Qiagen, Venlo, The Netherlands) in a 7900HT system (Applied Biosystems, Foster City, CA, USA).

4.6. MTT Assay

At the end of each testing time, the culture supernatants were removed, MTT solution (0.5 mg/mL) was added to each well, and the plates were incubated for 1 h at 37 °C. The MTT solution was removed, and isopropyl alcohol was added to dissolve formazan crystals. The absorbance at 570 nm was read on a microplate spectrophotometer (Applied Biosystem). shRNA targeting RNF7 were obtained from Sigma and have the following sequence:

TRCN0000298777 (#77):
CCGGCCGTGGTGAAACAGAAACAATCGAGTTGTTCTGTTTCACCCACAGGGTTTTTG

TRCN0000295933 (#33):
CCGGGTAATCCAGTGCCCTACAAAGCTCGAGCTTTGTAGGGACTCAGTTTTTG.

Acknowledgments: We thank all the members of the lab for critical reading of the manuscript.

Author Contributions: Gianluca Telesio, Ivan Scudiero and Romania Stilo conceived and designed the experiments; Maddalena Pizzulo, Pellegrino Mazzone, Tiziana Zotti, Serena Voccola, and Immacolata Polvere performed the experiments analyzed the data; Pasquale Vito wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Blonska, M.; Lin, X. NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res. 2011, 21, 55–70. [CrossRef] [PubMed]
2. Scudiero, I.; Vito, P.; Stilo, R. The three CARMA sisters: So different, so similar: A portrait of the three CARMA proteins and their involvement in human disorders. J. Cell. Physiol. 2014, 229, 990–997. [CrossRef] [PubMed]
3. Stilo, R.; Liguoro, D.; Di Jeso, B.; Formisano, S.; Consiglio, E.; Leonardi, A.; Vito, P. Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator. J. Biol. Chem. 2004, 279, 34323–34331. [CrossRef] [PubMed]
4. Scudiero, I.; Mazzone, P.; D’Andrea, L.E.; Ferravante, A.; Zotti, T.; Telesio, G.; De Rubis, G.; Reale, C.; Pizzulo, M.; Muralitharan, S.; et al. CARMA2sh and ULK2 control pathogen-associated molecular patterns recognition in human keratinocytes: Psoriasis-linked CARMA2sh mutants escape ULK2 censorship. Cell Death Dis. 2017, 8, e2627. [CrossRef] [PubMed]
5. Jordan, C.T.; Cao, L.; Roberson, E.D.; Pierson, K.C.; Yang, C.F.; Joyce, C.E.; Ryan, C.; Duan, S.; Helms, C.A.; Liu, Y.; et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 2012, 90, 784–795. [CrossRef] [PubMed]
6. Jordan, C.T.; Cao, L.; Roberson, E.D.; Duan, S.; Helms, C.A.; Nair, R.P.; Duffin, K.C.; Stuart, P.E.; Goldgar, D.; Hayashi, G.; et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. *Am. J. Hum. Genet.* 2012, 90, 796–808. [CrossRef] [PubMed]

7. Fuchs-Telem, D.; Sarig, O.; van Steensel, M.A.; Isakov, O.; Israeli, S.; Nousbeck, J.; Richard, K.; Winnepenninckx, V.; Vernooij, M.; Shomron, N.; et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. *Am. J. Hum. Genet.* 2012, 91, 163–170. [CrossRef] [PubMed]

8. Ammar, M.; Jordan, C.T.; Cao, L.; Lim, E.; Bouchlaka Souissi, C.; Jrad, A.; Omrane, I.; Kouidhi, S.; Zaraa, I.; Anbunathan, H.; et al. CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts. *Br. J. Dermatol.* 2016, 174, 330–337. [CrossRef] [PubMed]

9. Ammar, M.; Bouchlaka-Souissi, C.; Helms, C.A.; Zaraa, I.; Jordan, C.T.; Anbunathan, H.; Bouhraa, R.; Kouidhi, S.; Doss, N.; Dhaoui, R.; et al. Genome-wide linkage scan for psoriasis susceptibility loci in multiplex Tunisian families. *Br. J. Dermatol.* 2013, 168, 583–587. [CrossRef] [PubMed]

10. Eskin-Schwartz, M.; Basel-Vanagaite, L.; David, M.; Lagovsky, I.; Ben-Amotz, D.; Smirin-Yosef, P.; Atzmony, L.; Hodak, E. Intra-familial variation in clinical phenotype of CARD14-related Psoriasis. *Acta Derm. Venereol.* 2016, 96, 885–887. [CrossRef] [PubMed]

11. Feng, C.; Wang, T.; Li, S.J.; Fan, Y.M.; Shi, G.; Zhu, K.J. CARD14 gene polymorphism c.C2458T (p.Arg820Trp) is associated with clinical features of psoriasis vulgaris in a Chinese cohort. *J. Dermatol.* 2016, 43, 294–297. [CrossRef] [PubMed]

12. González-Lara, L.; Coto-Segura, P.; Penedo, A.; Eiris, N.; Díaz, M.; Santos-Juanes, J.; Queiro, R.; Coto, E. SNP rs11652075 in the CARD14 Gene as a risk factor for Psoriasis (PSORS2) in a Spanish Cohort. *DNA Cell Biol.* 2013, 32, 601–604. [CrossRef] [PubMed]

13. Inoue, N.; Dainichi, T.; Fujisawa, A.; Nakano, H.; Sawamura, D.; Kabashima, K. CARD14 Glu138 mutation in familial pityriasis rubra pilaris does not warrant differentiation from familial psoriasis. *J. Dermatol.* 2016, 43, 187–189. [CrossRef] [PubMed]

14. Mössner, R.; Frambach, Y.; Wilsmann-Theis, D.; Löhr, S.; Jacobi, A.; Weyergraf, A.; Müller, M.; Philipp, S.; Renner, R.; Traupe, H.; et al. Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients. *J. Investig. Dermatol.* 2015, 135, 2538–2541. [CrossRef] [PubMed]

15. Qin, P.; Zhang, Q.; Chen, M.; Fu, X.; Wang, C.; Wang, Z.; Yu, G.; Yu, Y.; Li, X.; Sun, Y.; et al. Variant analysis of CARD14 in a Chinese Han population with psoriasis vulgaris and generalized pustular psoriasis. *J. Investig. Dermatol.* 2014, 134, 2949–2996. [CrossRef] [PubMed]

16. Sugiuira, K.; Muto, M.; Akiyama, M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. *J. Investig. Dermatol.* 2014, 134, 1755–1757. [CrossRef] [PubMed]

17. Berki, D.M.; Liu, L.; Choon, S.E.; David Burden, A.; Griffiths, C.E.M.; Navarini, A.A.; Tan, E.S.; Irvine, A.D.; Ranki, A.; Ogo, T.; et al. Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. *J. Investig. Dermatol.* 2015, 135, 2964–2970. [CrossRef] [PubMed]

18. Zhu, K.; Shi, G.; Liu, H.; Zhu, C.; Fan, Y. Variants of CARD14 gene and psoriasis vulgaris in southern Chinese cohort. *An. Bras. Dermatol.* 2016, 91, 45–48. [CrossRef] [PubMed]

19. Van Nuffel, E.; Schmitt, A.; Afonina, I.S.; Schulze-Osthoff, K.; Beyaert, R.; Hailfinger, S. CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis. *J. Investig. Dermatol.* 2017, 137, 569–575. [CrossRef] [PubMed]

20. Scudiero, I.; Zotti, T.; Ferravante, A.; Vessichelli, M.; Vito, P.; Stilo, R. Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-kB activation and endoplasmic reticulum stress-induced cell death. *J. Cell. Physiol.* 2011, 226, 3121–3131. [CrossRef] [PubMed]

21. Afonina, I.S.; van Nuffel, E.; Baudetel, G.; Driege, Y.; Kreike, M.; Staal, J.; Beyaert, R. The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes. *EMBO Rep.* 2016, 17, 914–927. [CrossRef] [PubMed]

22. Howes, A.; O’Sullivan, P.A.; Breyer, F.; Ghose, A.; Cao, L.; Krappmann, D.; Bowcock, A.M.; Ley, S.C. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kB activation. *Biochem. J.* 2016, 473, 1759–1768. [CrossRef] [PubMed]
23. Harden, J.L.; Lewis, S.M.; Pierson, K.C.; Suárez-Fariñas, M.; Lentini, T.; Ortenzio, F.S.; Zaba, L.C.; Goldbach-Mansky, R.; Bowcock, A.M.; Lowes, M.A. CARD14 expression in dermal endothelial cells in psoriasis. *PLoS ONE* 2014, 9, e111255. [CrossRef] [PubMed]

24. Duan, H.; Wang, Y.; Aviram, M.; Swaroop, M.; Loo, J.A.; Bian, J.; Tian, Y.; Mueller, T.; Bisgaier, C.L.; Sun, Y. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. *Mol. Cell. Biol.* 1999, 19, 3145–3155. [CrossRef] [PubMed]

25. Sun, Y.; Li, H. Functional characterization of SAG/RBX2/ROCV/RNF7, an antioxidant protein and an E3 ubiquitin ligase. *Protein Cell* 2013, 4, 103–116. [CrossRef] [PubMed]

26. Swaroop, M.; Wang, Y.; Miller, P.; Duan, H.; Jatkoe, T.; Madore, S.; Sun, Y. Yeast homolog of human SAG/ROCV/Rbx2 Rbx2/Hrt2 is essential for cell growth, but not for germination: Chip profiling implicates its role in cell cycle regulation. *Oncogene* 2000, 19, 2855–2866. [CrossRef] [PubMed]

27. Miller, L.S. Toll-like receptors in skin. *Adv. Dermatol.* 2008, 24, 71–87. [CrossRef] [PubMed]

28. Moreno-García, M.E.; Sommer, K.; Shinohara, H.; Bandaranayake, A.D.; Kurosaki, T.; Rawlings, D.J. MAGUK-controlled ubiquitination of CARMA1 modulates lymphocyte NF-kappaB activity. *Mol. Cell. Biol.* 2010, 30, 922–934. [CrossRef] [PubMed]

29. Pedersen, S.M.; Chan, W.; Jattani, R.P.; Mackie, D.S.; Pomerantz, J.L. Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181. *Mol. Cell. Biol.* 2015, 36, 794–808. [CrossRef] [PubMed]

30. Oeckinghaus, A.; Wegener, E.; Welteke, V.; Ferch, U.; Arslan, S.C.; Ruland, J.; Scheidereit, C.; Krappmann, D. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. *EMBO J.* 2007, 26, 4634–4645. [CrossRef] [PubMed]

31. Akssentijevich, I.; Zhou, Q. NF-κB Pathway in Autoinflammatory Diseases: Dysregulation of Protein Modifications by Ubiquitin Defines a New Category of Autoinflammatory Diseases. *Front. Immunol.* 2017, 8, 399. [CrossRef] [PubMed]

32. Sebban, H.; Yamaoka, S.; Courtois, G. Posttranslational modifications of NEMO and its partners in NF-kappaB signaling. *Trends Cell Biol.* 2006, 16, 569–577. [CrossRef] [PubMed]

33. Yang, Y.K.; Yang, C.; Chan, W.; Wang, Z.; Deibel, K.E.; Pomerantz, J.L. Molecular Determinants of Scaffold-induced Linear Ubiquitylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling. *J. Biol. Chem.* 2016, 291, 25921–25936. [CrossRef] [PubMed]

34. D’Andrea, E.L.; Ferravante, A.; Scudiero, I.; Zotti, T.; Reale, C.; Pizzulo, M.; De La Morte, L.R.; De Maio, C.; Mazzone, P.; Telesio, G.; et al. The Dishevelled, EGL-10 and pleckstrin (DEP) domain-containing protein DEPDC7 binds to CARMA2 and CARMA3 proteins, and regulates NF-κB activation. *PLoS ONE* 2014, 9, e116062. [CrossRef]

35. Guitet, C.; Silvestri, E.; de Smaele, E.; Franzoso, G.; Vito, P. c-FLIP efficiently rescues TRAF-2−/− cells from TNF-induced apoptosis. *Cell Death Differ.* 2002, 9, 138–144. [CrossRef] [PubMed]

36. Scudiero, I.; Zotti, T.; Ferravante, A.; Vessichelli, M.; Reale, C.; Masone, M.C.; Leonardi, A.; Vito, P.; Stilo, R. Tumor necrosis factor (TNF) receptor-associated factor 7 is required for TNFα-induced Jun NH2-terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein. *J. Biol. Chem.* 2012, 287, 6053–6061. [CrossRef] [PubMed]

37. Guitet, C.; Vito, P. Caspase recruitment domain (CARD)-dependent cytoplasmic filaments mediate bcl10-induced NF-kappaB activation. *J. Cell Biol.* 2000, 148, 1131–1140. [CrossRef] [PubMed]